• Multi-cancer screening: Women wishing to screen for breast, ovarian, uterine or cervical cancer risk in the absence of symptoms.
• Family history of female cancers: First-degree relatives with breast, ovarian, uterine or cervical malignancy.
• Increased cancer risk factors: Hormonal history, genetic predisposition, lifestyle exposure or previous benign gynaecological findings.
• Annual or periodic cancer screening: Women seeking broader cancer screening alongside routine investigations.
• Limitations of single-organ screening: Situations where mammography, smear testing or ultrasound do not address overall cancer risk concerns.

Trucheck™ FemmeSafe evaluates circulating tumour-associated cells detectable in peripheral blood. These cells may be released from solid tumours and can provide early signals of tumour activity before clinical symptoms develop.

By assessing tumour-related cellular markers linked to several major female cancers, the test aims to support broader screening beyond single-organ approaches. Detection of these markers may help guide further investigation where screening results require clarification.

Results are considered alongside personal risk factors, clinical history and conventional screening such as imaging or cytology. Reviewing findings within this wider preventive health context can help inform decisions around follow-up testing or specialist referral.

Specimen

Whole blood 

Container

• 3 x EDTA tubes (purple colour cap) of 10 ml each

Volume

20 mL

Patient preparation

Not received blood transfusion at least 10 days prior to collection of the sample.
Not positive for HIV / HBV / HCV.

1. Crook, Timothy et al. “Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells.” Cancers vol. 14,14 3341 (2022), doi:10.3390/cancers14143341
2. Akolkar, Dadasaheb, et al. "Circulating ensembles of tumor-associated cells: a redoubtable new systemic hallmark of cancer." International journal of cancer 146.12 (2020): 3485-3494.
3. Ranade, Anantbhushan, et al. "Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk." Cancer Prevention Research 14.1 (2021): 11-16.
4. Gaya, Andrew, et al. "Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging." Cancer cytopathology 129.3 (2021): 226-238.